Market Overview - The Shanghai Composite Index is at 3343.05 points, slightly below the half-year line with a change of -0.11% [1] - The total trading volume of A-shares is 464.485 billion yuan [1] Stocks Above Half-Year Line - A total of 98 A-shares have surpassed the half-year line, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - *ST Tianshan: 13.33% deviation, closing price at 6.50 yuan, with a daily increase of 13.84% and turnover rate of 4.87% [1] - Xinghui Co., Ltd.: 10.53% deviation, closing price at 5.85 yuan, with a daily increase of 14.48% and turnover rate of 12.59% [1] - New Meixing: 9.82% deviation, closing price at 8.79 yuan, with a daily increase of 12.26% and turnover rate of 14.09% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Junshi Biosciences: 6.17% deviation, closing price at 30.73 yuan, with a daily increase of 6.96% [1] - Fuxiang Pharmaceutical: 5.24% deviation, closing price at 9.08 yuan, with a daily increase of 6.45% [1] - Jin Hong Group: 4.16% deviation, closing price at 9.08 yuan, with a daily increase of 10.06% [1] Summary of Deviation Rates - The report includes a detailed ranking of stocks based on their deviation rates from the half-year line, highlighting both high and low performers [1][2]

Core Viewpoint - Fuxiang Pharmaceutical plans to develop multiple plant-based meat products that closely mimic the texture and taste of real meat, leveraging new protein technology [1] Company Developments - The company aims to create over 10 consumer-oriented products through independent research and external collaborations [1] - Fuxiang has established the first domestic production line for microbial new protein with a capacity of 1,000 tons and is currently constructing a new line with an annual capacity of 20,000 tons [1] Industry Insights - According to Chen Jian, an academician from the Chinese Academy of Engineering, the production efficiency of new protein is 1,000 times higher than traditional livestock and fishery farming methods, with over 90% water savings and no need for pesticides or fertilizers [1] - The development of new protein can address key supply chain challenges in the meat, egg, and dairy industries, enhancing cost-effectiveness and sustainability, while also meeting national strategic needs for food security [1] - The industry has significant potential and market space for growth [1]

Group 1: Financial Performance and Market Trends - The company has seen a price decrease of 10-20% in key raw materials like 6-APA, which is expected to improve production costs for products like Shubatan and Tazobactam [2] - The company reported that the production cost of lithium battery electrolyte additives is now at an industry-leading level, although product prices remain low, resulting in lower profit margins [3] - The global market for Penem formulations is substantial and continues to grow, with some product prices showing an upward trend [3] Group 2: Product Development and Regulatory Approvals - The company has submitted the new food raw material registration for its microbial protein to the National Health Commission and received an acceptance notice, indicating progress towards market entry [3][11] - The company is actively expanding its production capacity in the microbial protein sector, with a current capacity of 1,200 tons per year and plans for a 20,000-ton project under construction [13] - The microbial protein market is projected to reach $290 billion by 2035, with a 22% market share for microbial fermentation protein, highlighting significant growth potential [10] Group 3: Strategic Focus and Future Outlook - The company is focusing on three main business segments: pharmaceutical manufacturing, lithium battery electrolyte additives, and synthetic microbial protein, aiming for sustainable growth [5][9] - The company anticipates that the increasing demand for alternative proteins driven by population growth will support the development of the microbial protein sector [10] - The management emphasizes that the pharmaceutical industry is a stable growth sector, with ongoing demand due to aging populations and increased health awareness [9][10] Group 4: Market Challenges and Investor Relations - The company acknowledges that its financial performance is influenced by market conditions, industry policies, and competition, which may lead to short-term volatility in stock prices [14][21] - The management is committed to improving operational efficiency and delivering better financial results to regain investor confidence [19][21] - The company is focused on maintaining transparency with investors regarding its financial health and future performance expectations [18][21]

Core Viewpoint - The company is actively engaging with investors and addressing concerns regarding its financial performance and future prospects, particularly in the pharmaceutical and new energy sectors. Financial Performance - The company reported that its production and operations are normal, and it is focusing on improving its performance despite facing uncertainties due to market conditions and industry policies [3][6][14]. - The company has been operating at a loss for three consecutive years, but management is committed to enhancing operational efficiency and performance across its key business segments [6][14]. Business Segments - The company is concentrating on three main areas: pharmaceutical manufacturing, lithium battery electrolyte additives, and synthetic biological protein [6][12]. - The pharmaceutical sector is expected to benefit from a stable market demand and the approval of new formulations, which will drive sales growth [13][15]. - The lithium battery additive business is projected to grow due to increasing demand in downstream applications like power and energy storage batteries [12][15]. - The synthetic biological protein segment is seen as a blue ocean market with significant growth potential, supported by government policies and rising demand for alternative proteins [12][15]. Regulatory Approvals - The company has submitted a new food raw material registration for its synthetic protein product to the National Health Commission and has received an acceptance notice, indicating progress towards market entry [2][10]. Market Outlook - The pharmaceutical industry is characterized as a stable growth sector, while the new energy sector is recognized as a strategic development area with ongoing demand growth [12][15]. - The synthetic biological protein market is anticipated to reach a substantial size by 2035, with microbial fermentation protein expected to capture a significant market share [13][15].

在本法律意见书中，本所律师仅对本次股东大会的召集、召开程序、出席本 次股东大会人员和召集人的资格、会议表决程序及表决结果是否符合《公司法》 《股东会规则》等相关法律、法规、规章、规范性文件及《公司章程》的规定发 表意见，并不对会议审议的议案内容以及该等议案所表述的事实或数据的真实性 及准确性发表意见。本所仅根据现行有效的中国法律问题发表意见，而未对有关 会计、审计和资产评估等非法律专业事项发表意见，亦未对非中国法律问题发表 意见。 北京市中伦律师事务所 关于江西富祥药业股份有限公司 2024 年年度股东大会的 法律意见书 致：江西富祥药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受江西富祥药业股份有限公 司（以下简称"公司"）委托，指派律师见证公司 2024 年年度股东大会（以下 简称"本次股东大会"）。本所律师根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《律师事务所从事 证券法律业务管理办法》等相关法律、法规、规章、规范性文件及《江西富祥药 业股份有限公司章程》（以下简称" ...

关于公司控股股东部分股份质押的公告 江西富祥药业股份有限公司 证券代码：300497 证券简称：富祥药业 公告编号：2025-037 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 | 柯喜丽 | 20,000 | 0.00% | 0 | 0 | 0% | 0% | 0 | 0% | 0 | 0% | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 景德镇市 | | | | | | | | | | | | 富祥投资 | 7,555,200 | 1.37% | 0 | 0 | 0% | 0% | 0 | 0% | 0 | 0% | | 有限公司 | | | | | | | | | | | | 合计 | 120,151,908 | 21.85% | 48,250,000 | 59,850,000 | 49.81% | 10.88% | 32,750,023 | 54.72% | 51,192,158 | 84.89% | 注1：上表中限售股份均为高管锁定股； 注2：上表若出 ...

证券代码：300497 证券简称：富祥药业 公告编号：2025-036 江西富祥药业股份有限公司 2024年年度股东大会会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更前次股东大会决议。 一、会议召开和出席情况 1、会议召开情况 江西富祥药业股份有限公司（以下简称："公司"）2024年年度股东大会于2025年 5月16日（星期五）下午14:30点在江西省景德镇市昌江区鱼丽工业区2号公司会议室召 开，会议由董事长包建华先生主持。 会议由公司董事会召集，会议采取现场记名投票与网络投票相结合的方式召开， 其中通过深圳证券交易所系统进行网络投票时间为：2025年5月16日上午9:15—9:25， 9:30-11:30，下午13:00—15:00；通过深圳证券交易所互联网投票系统投票的具体时间 为2025年5月16日9:15—15:00的任意时间。 会议的召开及表决等程序符合有关法律、行政法规、部门规章、规范性文件和公 司章程的规定。 2、会议出席情况 股东出席的总体情况： 通过 ...

江西富祥药业股份有限公司 关于参加江西辖区上市公司2025年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 证券代码：300497 证券简称：富祥药业 公告编号：2025-035 为进一步加强与投资者的互动交流，江西富祥药业股份有限公司（以下简称"公 司"）将参加由江西省上市公司协会举办的"2025年江西辖区上市公司投资者网上集 体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演APP，参与本 次互动交流，活动时间为2025年5月21日（周三）15:30-17:00。届时公司高管将在线 就公司2024年度业绩、公司治理、发展战略、经营状况、融资计划、股权激励和可持 续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 2025 年 5 月 12 日 江西富祥药业股份有限公司 董事会 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 董事会 2025 年 4 月 30 日 江西富祥药业股份有限公司全资子公司江西祥太生命科学有限公司因经营发展 需要，将总经理、法定代表人由包建华变更为刘英，并于近日办理了工商变更登记手 续，现已取得景德镇市市场监督管理局换发的《营业执照》，登记的相关信息如下： 8、经营范围：生命科学仪器研发，医学研究和试验发展，原料药制造、销售（凭 药品生产许可证经营）；化工原料（不含化学危险品）制造、销售；经营进出口业务。 （依法须经批准的项目，经相关部门批准后方可开展经营活动） 特此公告。 江西富祥药业股份有限公司 证券代码：300497 证券简称：富祥药业 公告编号：2025-034 江西富祥药业股份有限公司 关于全资子公司完成工商变更登记并换发营业执照的公告 1、统一社会信用代码：91360200563826869H 2、企业名称：江西祥太生命科学有限公司 3、类型：有限责任公司（自然人投资或控股的法人独资） 4、住所：江西省景德镇市景德镇高新区梧桐大道22号 5、法定代表人：刘英 6、注册资本：陆亿叁仟伍佰陆拾肆万壹仟 ...

Core Viewpoint - The company reported a challenging year with a total revenue of 1,177.85 million yuan and a net loss attributable to the parent company of 272.10 million yuan, highlighting the need for strategic adjustments in response to market conditions [17][18]. Company Overview - The company specializes in the research, production, and sales of anti-infection drug raw materials and intermediates, with a focus on expanding into lithium battery electrolyte additives and synthetic biology microbial protein [4][10]. Pharmaceutical Manufacturing Business - The pharmaceutical manufacturing segment generated sales revenue of 918.01 million yuan, accounting for 77.94% of total revenue, but faced challenges due to low prices of key products and high raw material costs [17]. - The company has made advancements in production processes, including the successful commercialization of sterile hezobactam sodium and the introduction of innovative enzyme methods to reduce production costs by 15%-20% [17][18]. Lithium Battery Electrolyte Additives - The lithium battery electrolyte additives business achieved sales revenue of 252.65 million yuan, representing 21.45% of total revenue, despite a decline in sales revenue due to falling prices [19]. - The company has expanded its market presence by obtaining EU REACH certification and IATF16949 certification, allowing for broader sales opportunities in international markets [20]. Microbial Protein Business - The company is a pioneer in the microbial protein industry, with a focus on developing sustainable protein sources that align with national strategic goals [21][22]. - The company has developed proprietary strains and technologies for producing microbial protein, achieving international recognition for its advancements [21][22]. Financial Performance - The company reported a total revenue of 1,177.85 million yuan and a net loss of 272.10 million yuan, indicating financial pressures amid competitive market conditions [17][18]. - The company has implemented asset impairment provisions totaling 156.72 million yuan due to cautious accounting practices in response to market challenges [27]. Strategic Initiatives - The management has launched a share buyback plan to boost investor confidence, with key executives collectively purchasing 2.8 million shares [27]. - The company is actively pursuing new business opportunities in the lithium battery and microbial protein sectors, supported by government policies and funding [21][24].